BCVA data for EUPATCH randomised controlled trial

This is a dataset associated with the publication: "Extended Optical Treatment versus Early Patching with a High-Dose Patching Regimen in Amblyopia: A Multicentre Randomized Controlled Trial",  published by the EUPATCH consortium. Authors: Frank Proudlock, Michael Hisaund, Gail Maconachie, Eleni Papageorgiou, Ali Manouchehrinia, Annegret Dahlmann-Noor, Payal Khandelwal, Jay Self Christina Beisse and Irene Gottlob. The dataset contains best-corrected visual acuity data from amblyopic and fellow eyes at key points in the trial along with demographic data. For furthe information on how to gain access please contact Frank Proudlock ([email protected]), Michael Hisaund ([email protected]) or Irene Gottlob ([email protected])</p

Income in Multiple Sclerosis Patients with Different Disease Phenotypes

<div><p>Background</p><p>Multiple sclerosis (MS) is a disease with profound heterogeneity in clinical course.</p><p>Objective</p><p>To analyze sources and levels of income among MS patients in relation to disease phenotype with a special focus on identifying differences/similarities between primary progressive MS (PPMS) and secondary progressive MS (SPMS).</p><p>Methods</p><p>A total of 6890 MS patients aged 21−64 years and living in Sweden in 2010 were identified for this cross-sectional study. Descriptive statistics, logistic, truncated linear, and zero-inflated negative binomial regression models were used to estimate differences in income between SPMS, PPMS and relapsing-remitting MS (RRMS) patients.</p><p>Results</p><p>RRMS patients earned almost twice as much as PPMS and SPMS patients (on average SEK 204,500, SEK 114,500, and SEK 79,800 in 2010, respectively). The difference in earnings between PPMS and SPMS was not statistically significant when analyzed with multivariable regression. The estimated odds ratio for PPMS patients to have income from earnings was not significantly different from SPMS patients (95% CI 0.98 to 1.59). PPMS and RRMS patients were less likely to receive benefits when compared to SPMS patients (by 6% and 27% lower, respectively).</p><p>Conclusion</p><p>Our findings argue for similarities between PPMS and SPMS and highlight the socioeconomic importance of preventing RRMS patients convert to SPMS.</p></div

The average of annual earnings of the patients by MS phenotype and age.

<p>The average of annual earnings of the patients by MS phenotype and age.</p

Average annual income of the patients by MS phenotype.

<p>Average annual income of the patients by MS phenotype.</p

Analysis approach.

<p>Analysis approach.</p

Descriptive data of the study population of MS patients by phenotype.

<p>Descriptive data of the study population of MS patients by phenotype.</p

Differences in income in 2010 among MS patients by phenotype.

<p>Differences in income in 2010 among MS patients by phenotype.</p

Extended Optical Treatment versus Early Patching with a High-Dose Patching Regimen in Amblyopia: A Multicentre Randomized Controlled Trial

No description supplie

MSJ783667_appendix_1 – Supplemental material for Predicting risk of secondary progression in multiple sclerosis: A nomogram

<p>Supplemental material, MSJ783667_appendix_1 for Predicting risk of secondary progression in multiple sclerosis: A nomogram by Ali Manouchehrinia, Feng Zhu, Daniela Piani-Meier, Markus Lange, Diego G Silva, Robert Carruthers, Anna Glaser, Elaine Kingwell, Helen Tremlett and Jan Hillert in Multiple Sclerosis Journal</p

sj-docx-1-tan-10.1177_17562864231198963 – Supplemental material for The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe

Supplemental material, sj-docx-1-tan-10.1177_17562864231198963 for The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe by Richard Nicholas, Jeff Rodgers, James Witts, Annalaura Lerede, Tim Friede, Jan Hillert, Lars Forsberg, Anna Glaser, Ali Manouchehrinia, Ryan Ramanujam, Tim Spelman, Pernilla Klyve, Jiri Drahota, Dana Horakova, Hanna Joensen, Luigi Pontieri, Melinda Magyari, David Ellenberger, Alexander Stahmann, Helmut Butzkueven, Anneke Van Der Walt, Vladimir Bezlyak, Carol Lines and Rod Middleton in Therapeutic Advances in Neurological Disorders</p